Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market

Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe

Shilpa Medicare Limited, a leading pharmaceutical and biotechnology company, announced that its 100% subsidiary Shilpa Biocare Private Limited has entered into a strategic partnership with Orion Corporation (Orion), a globally recognized pharmaceutical company headquartered in Finland, out-licensing its flagship product - Recombinant Human Albumin- for commercialisation across the European market. The product is currently under development.

Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large scale fermentation facility for manufacture of recombinant human albumin to address market demand for this life saving drug at a global scale. This collaboration marks a major milestone in Shilpa's expansion into global biosimilar and biopharmaceutical markets, leveraging Orion's strong regional presence, regulatory expertise, and well-established commercial infrastructure.

"Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental & manufacturing capabilities to bring recombinant human albumin to market," said Madhav Bhutada, Managing Director, Shilpa Biocare. "This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets."

Recombinant Human Albumin is a key plasma protein used in various therapeutic applications and as a critical component in vaccine and biologics manufacturing. Shilpa Medicare's recombinant human albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin.

"We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product," said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. "Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe."

This partnership reinforces both companies' commitment to advancing biotechnology-driven therapies and improving patient access to safer, sustainable, and next-generation biologics.